Ola Wallengren1, Kent Lundholm, Ingvar Bosaeus. 1. Department of Endocrinology, Diabetology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden. ola.wallengren@vgregion.se
Abstract
PURPOSE: Cachexia is associated with adverse outcomes. There is limited information on the impact of different diagnostic criteria of cachexia on patient centered outcomes. METHODS: We compared the prevalence of reduced quality of life (QoL), physical function and survival in palliative care cancer patients classified by different cachexia criteria. Four hundred and five patients with advanced cancer were included. Cachexia criteria were BMI, weight loss, fatigue, Karnofsky performance score, low handgrip strength, lean tissue depletion (DXA or arm muscle circumference) and abnormal biochemistry (inflammation, anemia or low serum albumin). QoL was assessed with a cancer specific questionnaire (EORTC QLQ-C30) and classified by cluster analysis. Dietary intake was obtained from a 4-day food record. Physical function was measured on a treadmill. RESULTS: Weight loss >2%, BMI <20, fatigue and CRP >10 mg/L were associated with adverse QoL, function and symptoms (odds ratios: 2.1, 2.9, 4.0 and 3.1 respectively, P < 0.05 for all). Fatigue, low grip strength and markers of systemic inflammation were associated with short walking distance (P < 0.05). Weight loss > 2%, fatigue, CRP > 10 mg/L and S-albumin < 32 g/L were associated with shorter survival (hazard ratios: 1.4, 1.6, 2.2 and 2.0 respectively, P < 0.05 for all). The prevalence of cachexia diagnosis varied from 12 to 85% using different definitions. CONCLUSIONS: Weight loss, fatigue and markers of systemic inflammation were most strongly and consistently associated with adverse QoL, reduced functional abilities, more symptoms and shorter survival. The prevalence of cachexia using different definitions varied widely; indicating a need to further explore and validate diagnostic criteria for cancer cachexia.
PURPOSE:Cachexia is associated with adverse outcomes. There is limited information on the impact of different diagnostic criteria of cachexia on patient centered outcomes. METHODS: We compared the prevalence of reduced quality of life (QoL), physical function and survival in palliative care cancerpatients classified by different cachexia criteria. Four hundred and five patients with advanced cancer were included. Cachexia criteria were BMI, weight loss, fatigue, Karnofsky performance score, low handgrip strength, lean tissue depletion (DXA or arm muscle circumference) and abnormal biochemistry (inflammation, anemia or low serum albumin). QoL was assessed with a cancer specific questionnaire (EORTC QLQ-C30) and classified by cluster analysis. Dietary intake was obtained from a 4-day food record. Physical function was measured on a treadmill. RESULTS:Weight loss >2%, BMI <20, fatigue and CRP >10 mg/L were associated with adverse QoL, function and symptoms (odds ratios: 2.1, 2.9, 4.0 and 3.1 respectively, P < 0.05 for all). Fatigue, low grip strength and markers of systemic inflammation were associated with short walking distance (P < 0.05). Weight loss > 2%, fatigue, CRP > 10 mg/L and S-albumin < 32 g/L were associated with shorter survival (hazard ratios: 1.4, 1.6, 2.2 and 2.0 respectively, P < 0.05 for all). The prevalence of cachexia diagnosis varied from 12 to 85% using different definitions. CONCLUSIONS:Weight loss, fatigue and markers of systemic inflammation were most strongly and consistently associated with adverse QoL, reduced functional abilities, more symptoms and shorter survival. The prevalence of cachexia using different definitions varied widely; indicating a need to further explore and validate diagnostic criteria for cancer cachexia.
Authors: Kent Lundholm; Ulla Körner; Lena Gunnebo; Petra Sixt-Ammilon; Marita Fouladiun; Peter Daneryd; Ingvar Bosaeus Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: P Daneryd; E Svanberg; U Körner; E Lindholm; R Sandström; H Brevinge; C Pettersson; I Bosaeus; K Lundholm Journal: Cancer Res Date: 1998-12-01 Impact factor: 12.701
Authors: Neil W Scott; Peter M Fayers; Neil K Aaronson; Andrew Bottomley; Alexander de Graeff; Mogens Groenvold; Chad Gundy; Michael Koller; Morten A Petersen; Mirjam A G Sprangers Journal: Qual Life Res Date: 2009-02-27 Impact factor: 4.147
Authors: Megan E Rosa-Caldwell; Jacob L Brown; David E Lee; Michael P Wiggs; Richard A Perry; Wesley S Haynie; Aaron R Caldwell; Tyrone A Washington; Wen-Juo Lo; Nicholas P Greene Journal: Appl Physiol Nutr Metab Date: 2019-10-16 Impact factor: 2.665
Authors: Ola Magne Vagnildhaug; Trude Rakel Balstad; Sigrun Saur Almberg; Cinzia Brunelli; Anne Kari Knudsen; Stein Kaasa; Morten Thronæs; Barry Laird; Tora Skeidsvoll Solheim Journal: Support Care Cancer Date: 2017-12-22 Impact factor: 3.603
Authors: Miriam N Lango; Brian Egleston; Carolyn Fang; Barbara Burtness; Thomas Galloway; Jeffrey Liu; Ranee Mehra; Barbara Ebersole; Kathleen Moran; John A Ridge Journal: Cancer Date: 2013-12-18 Impact factor: 6.860
Authors: Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar Journal: Semin Cancer Biol Date: 2017-12-30 Impact factor: 15.707
Authors: Livia Costa de Oliveira; Gabriela Travassos Abreu; Larissa Calixto Lima; Mariah Azevedo Aredes; Emanuelly Varea Maria Wiegert Journal: Support Care Cancer Date: 2020-02-07 Impact factor: 3.603
Authors: Antonia V Bennett; Bryce B Reeve; Ethan M Basch; Sandra A Mitchell; Mathew Meeneghan; Claudio L Battaglini; Abbie E Smith-Ryan; Brett Phillips; Thomas C Shea; William A Wood Journal: Qual Life Res Date: 2015-11-17 Impact factor: 4.147